BCL2 and pancreatic neoplasm: The protective effect overexpressing CrmA, which acts to suppress death receptor caspase activation, suggests the possibility that GSK-3 inhibition might sensitize to TRAIL through enhancement of initiator caspases such as caspase-8, as well as via anti-apoptotic molecules such as Bcl-2 and Mcl-1 in pancreatic cancer cells.